2003
Vulnerable Plaque Study Shows Correlation Between Lipid-Rich Plaques and Heart Attacks in Cath Lab Patients Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of...
FUTURE I and II Trials Utilize Everolimus with Bioabsorbable Polymer; Results Presented Today Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and...
Live Webcast Available Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, announced today that it will host an investor briefing...
Presentation Accessible Via Webcast Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, today announced that it will participate...
"Programmable" Polymer Capabilities Strengthen Guidant''s Development of Future Therapies for Coronary Artery Disease Indianapolis and Santa Clara, Calif. - Guidant Corporation (NYSE: GDT), a...
Company Outlines Progress Toward Drug Eluting Stent Milestones; Third Quarter and Full-Year 2003 Financial Guidance Affirmed Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in...
Additional Equity Investment Strengthens Guidant''s Commitment to the Development of Future Technologies for Heart Surgery Menlo Park, Calif. - Guidant Corporation (NYSE: GDT), a world leader in...
Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, will host a mid-quarter conference call to provide an update on the...
Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, today announced that the company''s board of directors declared a third...
Latest Addition to Pacemaker Portfolio Offers Improved Therapy Options While Maintaining Size and Longevity Brussels, Belgium and St. Paul, Minn. - Guidant Corporation (NYSE: GDT), a world leader...
Calls on Conference to Seize Historic Opportunity to Improve Quality and Expand Access Through Greater Choice, Competition and Innovation Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a...
World''s Smallest Dual Chamber System Offers Enhanced Therapies to Patients at Risk of Sudden Cardiac Death Indianapolis, Ind. and St. Paul, Minn. - Guidant Corporation (NYSE: GDT), a world leader...
Worldwide implantable cardioverter defibrillator revenues of $377 million, up 50 percent; Worldwide stent revenue of $224 million, down 2 percent; Favorable product mix generates 75.4 percent...
Next-Generation Stent Design and Excellent Clinical Results Offer Expanded Treatment Options for Patients Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of...
European Trial Demonstrates Low Restenosis Rate in Stenting of Small Vessels Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease,...
Cardiac Resynchronization Therapy-Defibrillator Represents the World''s Most Advanced System Indianapolis, Ind. and St. Paul, Minn. - Guidant Corporation (NYSE: GDT), a world leader in the...
Corporate Integrity Agreement Strengthens Guidant''s Commitment to Compliance Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) today announced that it has entered into a corporate integrity...
Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, will conduct a live webcast of its second quarter 2003 earnings conference...
European Approval Received; New Technology''s Clinical Trial Demonstrated Excellent Results Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and...
Financial Guidance Updated Based on Strong Sales Companywide; Quarterly Dividend to be Paid June 30 INDIANAPOLIS - Guidant Corporation (NYSE: GDT) today announced that the company has made a $10...
No Risk to Patients Implanted with ANCURE ENDOGRAFT System INDIANAPOLIS - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, today announced plans to...
X Technologies Receives FX miniRAIL U.S. Food and Drug Administration Approval; Conditions of X Technologies Acquisition Fulfilled; Agreement Expected to Close This Quarter Indianapolis, Ind. -...
Company''s Management to Provide Update on Recent Developments Live Webcast Available Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular...
No Risk to Patients Implanted with ANCURE ENDOGRAFT System INDIANAPOLIS - EndoVascular Technologies, Inc. (EVT), a subsidiary of Guidant Corporation, today announced that it has entered into a...
Second Clinical Trial Advances Efforts to Develop Minimally Invasive Treatment for Carotid Artery Disease Indianapolis, Ind. and Menlo Park, Calif. - Guidant Corporation (NYSE: GDT), a world...